ADC Therapeutics SA
PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES

Last updated:

Abstract:

The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

Status:
Application
Type:

Utility

Filling date:

28 Aug 2020

Issue date:

22 Apr 2021